Notícias

RapAdmin

AutophagyNew-2
AutophagyNew-21376×768 158 KB

An Australian team measured how fast autophagy, the cell’s self-recycling system, was running in immune cells from 94 patients with leg or neck artery disease and 19 plaque-free volunteers. They used a one-hour chloroquine test on fresh blood. Recycling rate (flux) was about 54 percent higher in patients, and conventional static markers could not detect the difference. Flux fell back toward normal in patients with severe limb disease plus active infection, which the authors read as exhaustion. Among 49 patients with the most severe leg disease, those with the lowest flux had more heart attacks, strokes and deaths over about two years.

The longevity world treats autophagy, the cell’s self-recycling system, as an unambiguous good. More is younger, less is older, and a long list of compounds and fasting protocols are sold on their ability to turn it up. A new study from Adelaide suggests the picture in human blood is messier, and more interesting.

Researchers at the South Australian Health and Medical Research Institute, Flinders University and Adelaide University took fresh blood from 94 people with serious artery disease and from 19 healthy volunteers. The patients had either narrowed leg arteries (peripheral arterial disease) or narrowed neck arteries (carotid stenosis). The volunteers’ heart scans showed no plaque at all. Most earlier studies took a single snapshot of autophagy markers. This team instead measured how fast the process was running. They split each blood sample in two and used the antimalarial drug chloroquine to block the final digestion step in one half for an hour. Then they measured how much of the autophagy marker LC3B-II piled up in the immune cells. The faster it piles up, the faster the recycling line is moving.

The result ran against expectations. Immune cells from patients with artery disease recycled about 54 percent faster than those from healthy controls. The difference held after the researchers statistically accounted for age, sex, diabetes, smoking, cholesterol and medication. The standard snapshot measurement found no meaningful difference at all, a reminder that static markers can miss what dynamic ones catch. Earlier snapshot studies had concluded that autophagy is reduced in artery disease.

The team’s interpretation is that chronic inflammation, oxidative stress and excess blood fats push immune cells to step up their housekeeping as a defense. That response appears to have limits. In patients with the most severe leg disease who also had an active foot or leg infection, the recycling rate had dropped back toward the level seen in healthy people. The authors read this as exhaustion rather than recovery.

The most eye-catching result comes from following patients for a median of about two and a quarter years. Among the 49 patients with chronic limb-threatening ischemia, those in the lowest quarter of recycling rates had far more heart attacks, strokes and deaths than those in the other three quarters. On paper, the higher groups had between 82 and 93 percent lower risk.

Those numbers need a large pinch of salt. They rest on just 15 events, spread across four groups and adjusted for six other factors. Statisticians know that set-up tends to inflate effects dramatically. The paper is also a preprint that has not been peer reviewed, and the healthy volunteers were on average 18 years younger than the patients.

The bigger idea survives the caveats. If a one-hour blood test can read how hard immune cells are working to cope with stress, it could offer a window into systemic disease that no cholesterol panel provides.

Actionable Insights

  • A high blood autophagy reading is not a youth score. People with artery disease had immune-cell recycling rates about 54 percent higher than healthy controls. That is a large effect, about 1.1 standard deviations. Pick one patient and one healthy person at random, and the patient has the higher reading about 78 percent of the time.
  • The reported 82 to 93 percent lower risk of heart attack, stroke or death for patients with higher readings comes from 15 events in 49 people with severe leg disease. Pulled back toward what blood biomarkers usually achieve, a more realistic estimate is roughly 40 percent lower risk, with a plausible range that includes no benefit at all.
  • Statin users had about 23 percent higher readings after adjustment, short of statistical proof. Metformin users showed no difference (about 1 percent lower).
  • Diabetes carried the largest risk signal in the severe-disease group, though that estimate is very imprecise.

Context and Source

Leitura Relacionada:

RapAdmin

RuckingVestWeightLoss
RuckingVestWeightLoss2752×1536 444 KB

A two-year follow-up of a small Wake Forest trial asked whether wearing a weighted vest while dieting helps older adults keep the weight off afterward. Eighteen adults in their early seventies, with obesity and arthritis, had lost about 10 to 11 kg on a six-month meal-replacement diet. Half of them had also worn a vest loaded to replace the weight they lost. About 19 months after the program ended, the diet-only group had regained everything, while the vest group was still 4.8 kg below its starting weight. The vest group’s resting metabolism barely fell during dieting. The diet-only group’s fell by about 240 kcal a day.

Losing weight is hard. Keeping it off is harder, and for older adults the rebound carries an extra cost, because regained weight can come back with proportionally more fat than was lost. A small study from Wake Forest University in North Carolina points to a low-tech way to tilt the odds: put the lost weight back on, in a vest.

The idea comes from the “gravitostat,” a hypothesis Swedish researchers proposed in 2018. In rodents, bone cells in the legs appear to sense how much weight the body carries and signal the brain to defend a set amount of fat. When a heavy capsule is implanted in a mouse, the animal sheds fat to compensate. If people have a similar sensor, dieting would register as lost load, and the body might respond by conserving energy and nudging appetite upward. A vest that restores the load could, in principle, blunt that response.

Carson DeLong, Kristen Beavers and colleagues went back to volunteers from an earlier trial in which older adults with obesity followed a six-month meal-replacement diet. Half were also asked to wear a vest for up to 10 hours a day, with weight added weekly to replace what they had lost. About two years after the start, 18 of the original 37 participants returned to be measured.

Both groups lost similar amounts during the diet, around 10 to 11 kg, or roughly 11 to 12 percent of body weight. The difference appeared later. By the two-year visit, the diet-only group had regained all of it and a little more. The vest group had regained only about half and was 4.8 kg below where it began.

The team suspects metabolism. Dieting usually lowers resting metabolic rate, the energy the body burns at rest, and that slowdown is often blamed for regain. In the diet-only group, resting metabolism dropped by about 240 kcal a day over six months. In the vest group it barely moved. Across all participants, people whose metabolism fell more during the diet tended to regain more afterward.

The caveats are large. With nine people per group, the weight difference could be chance, and its p-value of 0.10 misses the usual threshold. Only half the original volunteers came back, and they chose to. No one tracked diet, activity, or whether vest users kept wearing their vests. The vest also did not protect lean tissue: both groups lost about 3 kg of it. That makes the metabolic result harder to explain.

Still, the signal is not a one-off. The same group’s larger INVEST in Bone Health trial enrolled 150 older adults. A conference abstract covering a 21-person follow-up subset reported the same pattern: better-preserved resting metabolism with vests and less regain in the year after the program ended. That result is not yet peer reviewed, and it also fell short of statistical significance.

Other human tests of the gravitostat are mixed. A three-week Swedish trial found that heavy vests trimmed about 1.4 percent more body weight than light ones. A later five-week trial from the same group improved body composition without changing weight.

The appeal is obvious. A vest is cheap, needs no gym, and can be worn while doing the dishes. Whether it can do the heavy lifting of weight maintenance is a question only a properly sized trial can answer.

Actionable Insights

  • Treat a weighted vest as a low-cost experiment, not a proven tool. It was well tolerated in these trials, but its benefit for keeping weight off is unconfirmed.
  • How big could the benefit be? Two years out, vest wearers were about 5.7 kg (12.5 lb) lighter than diet-only participants. In standardized terms that difference is about 0.75, which statisticians would normally call moderate to large. With only nine people per group, though, the plausible true effect runs from about 1 kg worse to nearly 13 kg better, and small pilot studies usually overestimate.
  • The metabolic effect is the stronger number. During dieting, vest wearers burned about 220 kcal a day more at rest, roughly a slice of toast with peanut butter. Its standardized size (about 1.7) is very large, yet the difference had disappeared by two years.
  • Do not expect a vest to protect muscle. Both groups lost about 3 kg of lean mass. Progressive resistance training remains the better-supported option.
  • The trials used this protocol: add weight gradually, replacing half to most of what you lose, and wear the vest 6 to 8 hours a day while upright.
  • If you have knee or hip arthritis, ask a clinician first. This study did not report joint outcomes.

Context/Source

Leitura Relacionada:

RapAdmin

Screenshot 2026-09-28 at 2.01.08 PM
Screenshot 2026-09-28 at 2.01.08 PM1194×902 85.1 KB

A great longevity paper for kids age 8 to 18, from Matt Kaeberlein, Steve Austad, and Richard Miller. Print it out and give it to your kids, or teachers you know.

Three well-known aging biologists, Richard Miller, Steven Austad and Matt Kaeberlein, have written a children’s version of their new Frontiers in Science lead article. It first recaps the evidence that aging can be slowed in mice. That evidence includes calorie restriction, dwarfing mutations, and 14 drugs or drug combinations validated by the National Institute on Aging’s Interventions Testing Program (ITP). The best of these is rapamycin plus acarbose. The article then argues that the field’s real bottleneck is measurement. The authors propose “aging rate indicators” (ARIs): molecular changes shared by many kinds of slow-aging mice that show up within about eight months of treatment. ARIs could screen candidate drugs far faster than lifespan studies, and perhaps one day allow short human trials. The article contains no new data. The concept is plausible but has not yet been validated.

Every adult carries a mortality clock that doubles the risk of death roughly every eight years. For most of the last century, scientists assumed nothing could change how fast that clock ticks. A short article written for schoolchildren by three prominent aging researchers argues that this assumption is dead, at least in mice. The next problem, they say, is learning to read the clock’s speed.

Richard Miller of the University of Michigan, Steven Austad of the University of Alabama at Birmingham, and Matt Kaeberlein, adapted the piece from a longer lead article in Frontiers in Science. A panel of reviewers aged 10 to 15 vetted the children’s version. It contains no new experiments. Its value lies in how clearly it states the field’s central bottleneck.

The case that aging can be changed rests on three legs. Cutting calories by 30 to 40 percent extends rodent lifespan by a similar margin. Single-gene mutations, starting with the Ames dwarf mouse in 1996, can add 20 to 40 percent. Since 2003, the ITP has tested drugs at three sites in genetically mixed mice, and it has found 14 agents or combinations that extend lifespan. The standout is rapamycin plus the diabetes drug acarbose, which the authors report extended median male lifespan by 29 percent.

The trouble is time and money. A single mouse lifespan study costs several hundred thousand dollars and takes about four years, and roughly 85 percent of candidate drugs fail. In humans the problem is far worse: a trial long enough to detect slower aging would run 5 to 20 years.

The proposed fix is what the authors call aging rate indicators. The idea is a speedometer rather than an odometer. Epigenetic clocks and similar biomarkers try to estimate how old a body is, which means measuring at least twice, years apart. An aging rate indicator would reveal from a single sample whether a body has entered a slow-aging state.

The Miller lab found its candidates by looking for changes shared across very different slow-aging mice. These include dwarf mutants, calorie-restricted mice, and mice given rapamycin, acarbose, 17-alpha-estradiol or canagliflozin. The overlap is surprisingly broad:

  • Fat tissue makes more of UCP1, a heat-generating mitochondrial protein.
  • In fat, inflammatory immune cells give way to anti-inflammatory ones.
  • Muscle produces more of the exercise-linked protein FNDC5 and its fragment irisin.
  • The liver secretes more GPLD1, an enzyme tied to exercise benefits in the brain.
  • The hippocampus carries more BDNF and doublecortin, markers of nerve cell support and new neuron production.

These shifts appear after about eight months of treatment in groups of 10 to 20 mice. That is roughly four times faster than a lifespan study, at about one-twentieth of the cost.

The long game is human. If a handful of blood-borne indicators track slow aging in both mice and people, researchers could screen 20 candidate drugs in year-long trials of a few dozen volunteers. Only the one or two drugs that shift the markers would move on to full outcome trials.

Context/Source

  • Full title: Can Scientists Develop Pills That Slow Aging? (PDF version here)
  • Authors: Richard A. Miller, Steven Austad, Matt Kaeberlein
  • Institutions: University of Michigan (Department of Pathology and Geriatrics Center, Ann Arbor); University of Alabama at Birmingham (Department of Biology); Optispan, Inc. (Seattle)
  • Country: United States
  • Journal: Frontiers for Young Minds, published 17 September 2026.
  • Article type: A children’s adaptation of the lead article “Aging rate indicators and the search for anti-aging drugs”

RapAdmin

BioAgeNLRP3Poster
BioAgeNLRP3Poster2752×1536 499 KB

BioAge Labs presented a conference poster showing that BAL-1901, an oral drug that blocks the NLRP3 inflammasome, shifted a range of behaviors in 21-month-old mice toward those of 12-month-old controls. The treated mice moved more and faster, ate and drank in more youthful patterns, slept and rested differently, and behaved more like younger animals in social and exploratory tests. They also showed lower blood markers of inflammation (IL-6, serum amyloid P) and nerve and glial injury (GFAP, NfL). Behavior was tracked with an AI camera and microphone system inside the home cage. The data come from 12 mice per group, have not been peer reviewed.

Inflammation that simmers quietly for decades is one of the more plausible engines of aging. Researchers call it inflammaging, and one of its main ignition switches is NLRP3, a sensor protein inside immune cells. When NLRP3 detects cellular damage, including debris leaking out of stressed mitochondria, it assembles a molecular machine called the inflammasome, which releases the inflammatory messengers IL-1β and IL-18. Mice born without NLRP3 age more gracefully, and some studies report that they live longer. The practical question is whether a drug can reproduce that benefit when given late in life.

BioAge Labs, a publicly traded company in Emeryville, California, now says the answer may be yes, at least for behavior. Its scientists gave 21-month-old mice, roughly equivalent to people in their mid-sixties, a daily oral dose of an experimental NLRP3 blocker called BAL-1901. A comparison group of 12-month-old mice, closer to middle-aged humans, received a placebo.

Instead of relying on the usual short lab tests, the team housed the mice in cages fitted with a smart lid from Olden Labs. Infrared cameras and microphones logged movement, sleep, feeding, drinking, where animals spent their time, and how they interacted, around the clock and without human handling.

The old untreated mice behaved like old mice. They covered less ground, moved more slowly, spent longer eating, drank less, and kept more distance from cage mates. After treatment, many of these measures moved back toward the younger pattern. On several movement measures the treated old mice appear to outpace even the younger controls. Blood tests pointed the same way. Levels of IL-6, a general inflammation signal, and serum amyloid P, the mouse equivalent of the CRP that doctors measure in people, were lower in treated animals. So were GFAP and NfL, two markers that rise when the brain’s support cells are activated or nerve fibers are damaged.

The result matters mainly because of what BioAge is doing in people. The company’s lead NLRP3 drug, BGE-102, from the same chemical family, cut the inflammation marker hsCRP by more than 85 percent in a Phase 1 trial in people with obesity and is now in a Phase 2 cardiovascular risk study. A mouse poster showing broad functional improvement gives the company an aging story to go with its cardiology story.

The big idea still holds up as a hypothesis worth testing: that switching off one inflammatory sensor in old age can restore function rather than just slow its loss.

Actionable Insights

There is nothing here to act on directly. BAL-1901 is an internal research compound that is not yet available to anyone, and its human cousin BGE-102 is still in clinical trials.

What the study does support, weakly, is paying attention to chronic inflammation as a changeable part of aging. For readers, the practical steps are the familiar ones that lower NLRP3 activity and hsCRP: losing visceral fat, regular exercise, good sleep, avoiding smoking, and managing blood sugar. Asking your doctor for a high-sensitivity CRP test gives you a baseline. Levels under 1 mg/L are considered low risk, and levels above 2 mg/L consistently predict heart disease.

How big were the effects? The poster gives no averages or error bars that can be read (in the photo), so the true effect size is unknown. Working backward from the significance stars and the group size of 12, the smallest effects that could produce those stars are large. A treated mouse picked at random would outperform an untreated one roughly 73 to 92 percent of the time, depending on the measure. That sounds dramatic, but small studies routinely overestimate effects.

Context and Source

Leitura Relacionada:

RapAdmin

SASPandRisks
SASPandRisks2752×1536 499 KB

Researchers at UConn Health combined 38 blood proteins linked to cellular senescence into a single “SASP Score” using a transformer-based neural network trained on about 43,000 UK Biobank participants. In a held-out test group of 7,639 people followed for about 13 years, each 1 standard deviation increase in the score was associated with 41% higher mortality risk after adjustment for age, sex, BMI, smoking and other factors. The strongest links were to chronic kidney disease (more than double the risk per SD) and heart failure. The model was transferred to a different assay platform in a smaller exercise trial of 585 older adults. There, the score rose over 18 months in non-exercisers but not in exercisers.

Senescent cells are sometimes called zombie cells. They stop dividing but don’t die, and they keep releasing a mix of inflammatory signals, growth factors and tissue-degrading enzymes known as the senescence-associated secretory phenotype, or SASP. Many geroscientists think this secretory spillover is one of the ways aging spreads from tissue to tissue. The practical problem is measurement. Senescent cells are rare and scattered, and nobody can biopsy every organ. Blood-borne SASP proteins are the obvious workaround, but single proteins are noisy and none of them is specific to senescence.

This study tries to solve the problem by pooling signals. The team selected 38 plasma proteins that change in the same direction across multiple cell types and senescence triggers. They fed these into a guided autoencoder built on transformer architecture, the same basic machinery behind modern language models. The network compressed the 38 proteins into one number, using chronological age as a training guide so the score would capture aging-related structure rather than random variation.

In the UK Biobank test group, the score behaved like a credible aging measure. It correlated strongly with age and with established biological age measures, including PhenoAge and a proteomic aging clock. It was higher in smokers, people with central obesity, people with hypertension or high cholesterol, and frail participants. After adjusting for conventional risk factors, a higher score predicted death and a range of chronic conditions. Kidney disease, heart failure, COPD, delirium, heart attack and dementia showed the clearest signals. The composite also outperformed each of its 38 component proteins on its own.

The top contributors were GDF15, CXCL9, PGF, osteoprotegerin (TNFRSF11B) and CCL20. For readers who follow mitochondrial biology, GDF15 leading the list matters. GDF15 is a well-characterized mitochondrial stress signal and one of the most reliable aging proteins in plasma. However, it is not specific to senescent cells.

The second selling point is portability. Most proteomic clocks only work on the platform they were trained on. Here the model was fine-tuned on a different technology, a Luminex immunoassay panel, in the MEDEX trial of adults aged 65 to 84. In that cohort, the score climbed significantly over 18 months in participants who did not exercise. It stayed statistically flat in those assigned to combined aerobic and resistance training. The authors read this as exercise holding back senescence accumulation.

That conclusion runs ahead of the data. The formal test of whether the two groups’ trajectories differed did not reach significance. A pattern where one group changes “significantly” and the other does not is not the same as a significant difference between groups. The exercise finding is suggestive at best.

The larger contribution is methodological: a transferable, open-code composite that trials of senolytics and senomorphics could use as a secondary endpoint. Whether it measures senescence specifically, rather than general inflammation, kidney function and mitochondrial stress, remains an open question.

Actionable Insights

This score is a research tool, not a test you can order. The practical lessons are indirect.

First, the factors associated with a higher SASP Score are familiar and modifiable: smoking, high waist-to-hip ratio, high blood pressure and high cholesterol. These are cross-sectional associations, so they do not prove that fixing them lowers senescence burden. They are still consistent with standard cardiometabolic advice.

Second, exercise. Over 18 months, the non-exercise group’s score rose by 0.211 units. The exercise group’s score rose by 0.075 units, a rise about 64% smaller. The gap between groups was roughly 0.14 units, and if the score is scaled near standard deviation units, that is a small effect. It was also not statistically significant in the head-to-head test. Treat it as a hint that twice-weekly supervised aerobic and resistance training may slow a senescence-linked protein signature, not as proof.

Third, the risk signal. Each 1 SD higher score carried 41% higher mortality risk. In absolute terms, that roughly moves 13-year risk of death from about 11% to about 15%. For kidney disease, risk moved from about 6% to about 12%.

Finally, if you track GDF15 or other inflammatory markers privately, these data support their prognostic value, but not their use as intervention targets.

Context and Source

  • Open Access Paper: A Deep-Learning Based Biomarker of Systemic Cellular Senescence Burden to Predict Mortality and Health Outcomes, published: 25 September 2026.
  • Institution: UConn Center on Aging, UConn Health (Farmington, Connecticut), with Washington University School of Medicine, UC San Diego and the University of Connecticut Department of Statistics
  • Country: USA (UK Biobank data)
  • Journal: Aging Cell, 2026, volume 25, e70737
  • Impact evaluation: Aging Cell has a 2025 Journal Impact Factor of 7.7 in the 2026 Journal Citation Reports release, with a five-year JIF of 8.9. The impact score of this journal is 7.7, evaluated against a typical high-end range of 0 to 20+ for aging and geroscience journals (Nature Aging sits near the top), therefore this is a High impact journal.

Leitura Relacionada:

RapAdmin

DietMemory
DietMemory2752×1536 457 KB

A Singaporean cohort of 892 Chinese adults, whose diets were recorded at around ages 47, 67 and 74, found that closer adherence to the DASH diet at each life stage was linked to better verbal memory in their 70s. Of the seven cognitive domains tested, verbal memory was the only one that tracked diet. Midlife diet was linked to more white matter volume in language-related tracts. Diet in the 60s was linked to less white matter hyperintensity burden and lower cortical “free water,” an MRI marker thought to reflect neurovascular inflammation. Each brain measure statistically explained about 12% of the diet and memory link. People who improved a poor or average diet after midlife had better memory than those whose diets stayed poor. The effects are modest, the design is observational, and the paper is a preprint that has not been peer reviewed.

Most of what we know about diet and the ageing brain comes from studies that ask people what they ate once and then check on them a few years later. That design cannot tell you whether the diet you ate at 45 still matters at 75, or whether it is too late to change course at 65. A team at the National University of Singapore had an unusual resource for answering those questions. They drew on the Singapore Chinese Health Study, which enrolled more than 63,000 adults in the 1990s, and followed a subset of 892 people for up to 28 years.

Diet was scored against the DASH pattern, originally designed to lower blood pressure. It rewards fruit, vegetables, whole grains, nuts, legumes and dairy and penalises red and processed meat and sugary drinks. Scores were recorded in midlife (ages 44 to 55), early old age (61 to 73) and late life (68 to 82). In late life, participants completed nine cognitive tests covering seven domains and had detailed brain scans.

The headline result is narrow but consistent. Better DASH adherence at every stage went with better verbal memory, which here means the ability to learn and recall a spoken word list. Midlife diet still predicted memory when all three diet measurements were entered into the same model, which suggests that eating habits from two decades earlier carry information that later diet does not fully capture. Processing speed, attention, executive function, visuospatial skill, visual memory and language showed no significant links.

The brain scans suggest two different routes, depending on timing. Midlife diet was linked to larger white matter volume in the long association tracts, such as the arcuate and superior longitudinal fasciculi, that carry language signals across the brain. Diet in the 60s was linked to two other signs of healthier brain tissue: fewer white matter lesions around the basal ganglia, a classic marker of small vessel disease, and lower free water in frontal and occipital cortex. The authors read this as a story in which a good diet builds structural reserve in midlife and dampens vascular and inflammatory damage later.

The most practical finding concerns people who changed their diet. Participants who began with low or average diet quality in midlife but improved it afterwards had better late-life verbal memory than those who stayed low. The “average-improving” group was statistically indistinguishable from the consistently high group on memory and cortical free water, though not on white matter volume.

The caveats are large. This is an association study, so wealthier or more health-conscious people may simply eat better and also have better memory. Only about 2% of the original cohort returned for the brain scans, and survivors are healthier than those who dropped out. The diet questionnaire shrank from 165 items at baseline to 21 items later, which complicates comparisons across time. The brain and memory measures were taken on the same day, so the “mediation” cannot establish which came first. The effects are small, roughly a tenth of a standard deviation in memory score for each standard deviation of diet quality.

Still, the direction is consistent with trial data showing that DASH lowers blood pressure and with large cohort data on midlife diet and cognition. The message is modest but useful: diet quality seems to matter across adulthood, and improving it after midlife is associated with better outcomes.

Actionable Insights

The practical message: move your eating toward a DASH-style pattern at any age. That means more vegetables, fruit, whole grains, legumes, nuts and dairy, and less red and processed meat and sugary drinks. Improving from an average diet after midlife was linked to memory scores close to those of lifelong healthy eaters.

How big is the benefit? Memory scores were scaled so the average is 50 and a typical spread (one standard deviation) is 10 points. Each additional DASH point in midlife was linked to about 0.22 extra memory points. Moving one typical step up in diet quality (about 4.6 DASH points) works out to roughly 1 memory point, or about 0.1 standard deviations. That is small for an individual. Going from the consistently worst diet group to the consistently best was linked to roughly 5 points, or about half a standard deviation (estimated from the paper’s figures). That is a meaningful difference, similar to the memory gap between people several years apart in age. The “average-improving” group scored about 4 points above the consistently poor group (about 0.4 standard deviations).

Treat these as upper-bound estimates from observational data. Blood pressure control is the most plausible pathway, so pair the diet with blood pressure monitoring. The study could not score sodium, so it cannot tell you anything about salt reduction.

Context and Source

Leitura Relacionada:

RapAdmin

ConboyDMA-2
ConboyDMA-22752×1536 354 KB

In a new interview Irina Conboy has suggested the drug combination “mechanism of action” that her company has recently announced, and has been testing in people (including herself). In the video she states (see below) that her new injection drug combination (two drugs) operates on the same principles. See the link at the bottom for the full interview, and read the summary below of the paper that was published last year that tested the three-drug combination.

A UC Berkeley team combined two cheap, widely available drugs (metformin and dichloroacetate) with a ten-fold reduced dose of the experimental senolytic navitoclax (ABT-263), producing a cocktail they call DMA. The premise is that senescent cells and cancer cells share a specific metabolic weakness: both have poor mitochondrial efficiency and limited ability to ramp up glycolysis when stressed. Squeeze that weakness and their ATP supply collapses, which lowers the apoptotic threshold enough that a sub-toxic dose of navitoclax finishes the job. Healthy cells, with intact metabolic flexibility, absorb the same insult without dying. In culture the cocktail killed roughly 60 percent of senescent fibroblasts and nearly all of a navitoclax-resistant breast cancer line while sparing neural precursors, hepatocytes and non-senescent fibroblasts. In mice, the low navitoclax dose largely avoided the platelet crash that has blocked clinical translation of this drug class. Old mice dosed intermittently from about 18 months of age lived longer than vehicle controls, with median lifespan rising from 815 to 1002 days. The lifespan arm used nine mice per group.

The senolytics field has a drug it likes and cannot use. Navitoclax kills senescent cells efficiently by blocking BCL-2 family survival proteins, but platelets depend on the same proteins, so effective doses drive platelet counts down toward dangerous territory. A decade of clinical work has not solved this. Whole classes of cancer sidestep the drug entirely by leaning on MCL-1, a relative that navitoclax does not touch.

The Berkeley approach does not try to build a better navitoclax. It tries to make cells so metabolically fragile that a small dose is enough.

The logic rests on a quiet similarity between two cell types normally studied apart. Senescent cells and tumor cells both run inefficient mitochondria, leak protons across the inner membrane, and lean heavily on glycolysis. Metformin blocks complex I of the electron transport chain and dampens glycolysis. Dichloroacetate inhibits pyruvate dehydrogenase kinase, forcing pyruvate back into mitochondria and shifting the cell toward the oxidative phosphorylation it is bad at. Applied together, these two push a cell to use a system that is already broken while removing the backup. A healthy fibroblast has glycolytic reserve to fall back on. A senescent one, the Seahorse data show, does not.

The measurements bear this out. ATP in senescent and MCF-7 breast cancer cells fell close to background under the full combination, while healthy cells held their levels steady. Neither drug alone did this. When senescent cells were challenged with FCCP, a chemical uncoupler that demands maximum respiration, healthy cells surged and senescent cells could not respond at all. Adding ATP back to the medium partially rescued the senescent cells, which supports the energy-collapse explanation without fully proving it.

In vivo the picture is thinner but interesting. Two weeks of dosing improved treadmill endurance in old mice. Serum protein profiles, including inflammatory and SASP factors, shifted toward patterns seen in young animals. Mice given repeated two-week courses from about 18 months lived measurably longer than controls.

Two things this study did not do deserve equal billing. No tumor-bearing animal was ever treated, so the cancer half of the title rests entirely on cell culture. And no tissue was examined for senescent cell burden after dosing, so senolysis in a living mouse remains inferred rather than demonstrated. The lifespan signal comes from nine animals per arm against controls that died younger than a well-run mouse colony should produce.

Overall, the idea is sound and unusually cheap.

Actionable Insights

The active killing agent is navitoclax, an investigational drug that is not available, and the two accessible components did essentially nothing on their own at any concentration tested. That is the most useful practical finding in the paper for anyone currently taking metformin as a senolytic: in this system, metformin alone, dichloroacetate alone, and the two together produced no meaningful senescent cell clearance, while the three-drug combination cleared roughly 60 percent of them in standard culture and about 90 percent under oxygen levels closer to real tissue.

Scale matters here. The cell culture work used 5 millimolar metformin. Oral metformin in people produces plasma levels around 10 to 40 micromolar, roughly 100 to 500 times lower. Dichloroacetate at clinical doses causes dose-dependent peripheral neuropathy, and no neurological assessment was performed in these mice.

The mouse numbers, translated plainly: median lifespan rose 23 percent (815 to 1002 days, a gain of 187 days) in animals whose treatment began at about 18 months. Average lifespan rose about 14 percent. Treadmill endurance improved by roughly 20 percentage points relative to controls, a standardized effect of about 0.8, which is a large effect statistically but was measured in 11 treated versus 17 control animals. Platelets held at 70 percent of normal on the combination versus 25 percent on full-dose navitoclax.

Context and Source

Leitura Relacionada:

RapAdmin

SILtheory
SILtheory2752×1536 357 KB

This narrative review from three Italian immunologists proposes the “Silent Infection Load” (SIL) hypothesis. It argues that the lifelong total of infections that cause no symptoms contributes to inflammaging, the chronic low-grade inflammation of old age. These include common respiratory viruses, mild gut infections, herpesviruses that wake up without symptoms, colonizing bacteria, and low-level leakage of microbes across damaged barriers. The authors say each event causes a small, contained burst of immune activity. That burst stresses blood vessel linings, fragments mitochondria, activates complement, and disturbs stem cells. Repair is incomplete each time, so the damage adds up over decades. They present this as an evolutionary trade-off. Tolerating microbes helped people survive early in life, and the cost only shows up in the long lives people live today. The authors say openly that most of the evidence is indirect, and they propose vaccination as the main way to test the idea and act on it.

Most of us think of infection as an event: a fever, a lost week, then recovery. A new review from three Italian immunologists argues that the infections that matter most for aging may be the ones we never feel.

Andrea Cossarizza of the University of Modena and Reggio Emilia and colleagues call their idea the Silent Infection Load. Over a lifetime, the body quietly fights off a near continuous stream of microbes. These include rhinoviruses and seasonal coronaviruses, stomach bugs that never get past a queasy afternoon, herpesviruses such as cytomegalovirus and Epstein-Barr virus that sleep in our cells and periodically wake, and bacteria living on skin, gums and mucosa. The authors argue that each encounter triggers a small, contained burst of immune activity, which they call a micro-storm.

A micro-storm never raises a fever. According to the review, though, it does raise signalling molecules such as IL-6 and TNF, loosen the seals between cells lining small blood vessels, fragment mitochondria, and switch on complement, a cascade of blood proteins that tags and attacks invaders. Each episode clears, but the authors contend repair is rarely complete. A slightly leakier vessel, a more damaged mitochondrion, a stem cell pushed out of its resting state one more time: over decades, these leftovers could add up to the inflammation that feeds frailty, heart disease and dementia. The process may also feed itself. An aging immune system controls latent viruses less well, which means more reactivations and more inflammation.

The evolutionary framing is the most interesting part. Wiping out every microbe would cost too much energy and cause too much collateral damage, so tolerating some persistence was the affordable strategy. Few ancestral humans lived long enough for the late-life bill to arrive. Now most of us do. On this view, inflammaging is not the immune system breaking down. It is the running cost of a design built for a shorter life.

The practical angle is vaccination. If silent infections are part of the problem, preventing them should slow inflammaging. The authors cite evidence linking shingles vaccination to lower dementia rates. They also argue that a future cytomegalovirus vaccine could matter more for aging than for infection control.

The caveats are large, and to their credit the authors state them. Almost no evidence comes from people followed over time with truly silent infections. Most of it is borrowed from severe infections, cell culture and animal work, then extrapolated downward. Their own grading rates only latent herpesviruses as strongly supported. They also present the silent load as an amplifier of other aging drivers, not a main cause.

Field data complicate the picture further. The Tsimane of Bolivia carry heavy infection burdens and high inflammatory markers, yet they have some of the lowest rates of coronary artery disease ever measured. More infection does not straightforwardly mean worse aging.

What the review offers is a testable agenda. Build an index of lifetime silent infection from antibody profiling and blood markers, track it in aging cohorts, and use vaccine rollouts as experiments. Until then, the Silent Infection Load is a well-argued hypothesis, not a finding.

Actionable Insights

This is a review with no new data, so any benefits come from the human studies it cites, not from the paper itself.

  1. Get the recombinant shingles vaccine if you are eligible. This is the strongest actionable signal. In a natural experiment in Wales, people who became eligible for shingles vaccination were about 20% less likely (relative) to receive a new dementia diagnosis over 7 years, roughly 3.5 fewer diagnoses per 100 people. A separate US records study found about 17% more dementia-free time over 6 years with the recombinant vaccine than with the older live vaccine. That works out to roughly five extra months without a diagnosis. [Confidence: Medium. The Welsh design is unusually strong for observational data, but the mechanism is unproven.]
  2. Stay current on influenza, RSV (older adults) and pneumococcal vaccines. These reduce symptomatic disease and some silent carriage or shedding. No trial has yet shown that they slow inflammaging itself. [Confidence: Low for the aging benefit.]
  3. Take periodontal health seriously. Gum pathogens are one of the more plausible sources of chronic low-grade systemic inflammation, but the evidence is associative. [Confidence: Low to Medium.]
  4. Cytomegalovirus has no vaccine yet. Its association with mortality in older adults is real but modest and confounded, so there is no clinical action for it today.

Context and Source

  • Open Access Paper: The silent infection load: How lifelong asymptomatic infections may contribute to inflammaging as an evolutionary trade-off of longevity, 3 September 2026.
  • Institutions: University of Modena and Reggio Emilia; IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Milan; IRCCS Fondazione Don Carlo Gnocchi, Milan; University of Milan
  • Country: Italy
  • Journal: Ageing Research Reviews
  • Impact evaluation: The impact score of this journal is 15.5 (2025 Journal Impact Factor, 2026 JCR release; CiteScore 20.6), evaluated against a typical high-end range of 0 to 60+ for top general science and review journals, therefore this is a High impact journal.

Leitura Relacionada:

RapAdmin

ChildhoodLongevity
ChildhoodLongevity2752×1536 436 KB

This review proposes the “Adaptive Cost Hypothesis”: many non-communicable diseases (heart disease, type 2 diabetes, cancer, dementia) are not mainly lifestyle-mismatch diseases but the delayed costs of biological settings that helped our ancestors survive to reproduce. Early-life adversity is argued to tune immune, metabolic, stress and oxytocin systems through DNA methylation. These settings pay off in youth and do damage when they run for 70 to 90 years. The authors support the idea with evidence from hunter-gatherer populations, epigenetic clocks, childhood adversity studies and a 2026 mouse sepsis experiment. They recommend moving prevention toward pregnancy and early childhood and redefining healthy ageing as preserved function rather than normal lab values.

Why do people who do everything right still get heart disease, diabetes and dementia? A new review from the Luxembourg Institute of Health argues that the usual answer, that modern lifestyles clash with Stone Age bodies, is only half the story. The other half, say Jonathan Turner and colleagues, is that much chronic disease is the delayed bill for biological settings that helped our ancestors survive long enough to have children.

They call it the Adaptive Cost Hypothesis. It builds on an old idea from evolutionary biology. Selection cares about reproduction, so traits that help you survive to 30 are favoured even if they cause trouble at 75. The authors combine this with evidence that early experience tunes the body through chemical tags on DNA. A child who grows up with threat, hunger or neglect may develop a hair-trigger immune system, a reactive stress axis, a weaker oxytocin system and a metabolism built to store calories. In a dangerous world these settings help. Run them for eight decades and, the authors argue, you get chronic inflammation, stiff arteries, insulin resistance and overactive brain immune cells that feed dementia.

The central claim is that this is not just mismatch. Even when adult life matches what childhood programming expected, the programme itself wears the body down, because nothing selected it to run that long.

The supporting evidence is indirect and drawn from many sources. The Tsimane of Bolivia, forager-farmers who are lean and very active, have some of the cleanest arteries ever measured, yet some coronary calcium and dementia still appear with age. Epigenetic clocks track age closely even in healthy people. Adults with hard childhoods show more inflammation, altered methylation of the oxytocin receptor gene and more heart disease decades later. A 2026 Nature mouse study adds a molecular example: a heart pathway that protects young mice during sepsis kills old mice, and blocking it saved old animals while harming young ones.

The authors draw practical conclusions. Prevention should move upstream to prenatal care, support for new parents and reducing childhood adversity, and methylation clocks should be used to judge within a few years whether such programmes work. Healthy ageing, they argue, should mean keeping independence and a clear mind, not chasing perfect blood numbers. Therapies aimed at ageing itself, such as senolytics or partial reprogramming, fit the logic better than treating each disease one at a time.

The weaknesses are substantial. The paper contains no new data. Several of the studies it relies on do not test what it implies. The CALERIE diet trial never measured early-life programming, and the Look AHEAD lifestyle trial did not compare early with late intervention. Epigenetic clocks are built to predict age, so their accuracy says little about whether ageing is programmed. The authors’ own source on hunter-gatherer lifespans reports that the most common adult age at death in those groups is around 70, which undercuts the claim that human biology was “designed” for 40 to 60 years.

Even so, the paper asks a useful question in testable form: how much late-life disease can lifestyle realistically prevent, and how much is set early? The answer matters for where prevention money goes.

Actionable Insights

  1. Lifestyle still does most of the work you can control. The Tsimane are the paper’s best example of an intrinsic “floor,” yet about 85% of Tsimane adults had zero coronary artery calcium. That is a very large protective effect from diet and activity, and it is the modifiable part of risk.
  2. Treat a difficult childhood like a family history. People with four or more adverse childhood experiences have roughly twice the odds of heart disease and cancer as people with none. If your baseline heart disease risk is 6%, doubling the odds puts you at about 11 to 12%. That justifies earlier checks of blood pressure, lipids, glucose and inflammatory markers.
  3. For parents and policymakers, early investment may have unusually large returns. In the small Abecedarian early-childhood trial, men who received the program had systolic blood pressure about 17 points lower in their mid-30s. The sample was small, so treat this figure as optimistic.
  4. Do not expect midlife weight loss alone to erase cardiovascular risk. In Look AHEAD, sustained weight loss improved blood sugar and fitness but did not measurably reduce heart attacks or strokes over about 10 years.
  5. Aim for function (strength, cognition, independence) over perfect lab numbers.

Context and Source

  • Open Access Paper: Living beyond our evolutionary warranty: Why non-communicable diseases may be the inevitable costs of an extended lifespan, November 2026.
  • Institutions: Luxembourg Institute of Health, Department of Infection and Immunity (Luxembourg); Swedish University of Agricultural Sciences, Department of Animal Environment and Health (Sweden)
  • Countries: Luxembourg and Sweden
  • Journal: Ageing Research Reviews
  • Impact evaluation: In the 2026 Journal Citation Reports release, based on 2025 citation data, the journal’s impact factor is 15.5, it ranks third of 72 journals in Geriatrics and Gerontology, and its Elsevier CiteScore is 20.6 therefore this is a High impact journal.

Leitura Relacionada:

RapAdmin

AirPollutionAccelAging
AirPollutionAccelAging2752×1536 425 KB

This review from Tampere University and Karolinska Institutet brings together evidence that air pollution speeds up biological aging itself, not just damage to one organ at a time. Fine and ultrafine particles, traffic exhaust and smoke from indoor solid-fuel cooking are linked to oxidative stress, inflammaging, mitochondrial damage, telomere erosion and cellular senescence. The strongest human signals appear in composite blood-chemistry measures (Klemera-Doubal biological age, PhenoAge) and frailty indices. Epigenetic clocks are the notable exception: they fail at the meta-analytic level. The authors argue that biological aging partly mediates the link between pollution and death, disease and hospitalization. Switching to clean cooking fuels and improving regional air quality are associated with partial reversal. Get N95 masks if you live in an area where forest fires are common.

Most people think of air pollution as a lung problem, or at most a heart problem. A new review from researchers in Finland and Sweden argues that this view is too narrow. They propose that fine particles, traffic exhaust and smoke from indoor cooking fires act on the machinery of aging itself. On this account, pollution pushes the whole body toward an older physiological state instead of damaging one organ at a time.

Parinaz Poursafa and Juulia Jylhävä collected epidemiological and laboratory work across every major way scientists now measure biological age. That range runs from DNA methylation clocks and telomere length to blood-chemistry composites and frailty scores. Anyone who follows geroscience will recognize the proposed mechanism. Particles loaded with transition metals and polycyclic aromatic hydrocarbons generate reactive oxygen species. That oxidative load damages mitochondrial DNA, activates the NLRP3 inflammasome, shifts methylation patterns, erodes telomeres and pushes cells into senescence. Senescent cells then release inflammatory signals that push neighboring cells into the same state, so the damage can outlast the exposure.

The more useful finding concerns which measures actually detect this effect. The ones that respond most reliably to pollution are the least glamorous: Klemera-Doubal biological age, blood-based PhenoAge and frailty indices. All of them are built from routine markers such as CRP, albumin, glucose and white cell count. The fashionable epigenetic clocks hold up worse on close inspection. A 2026 meta-analysis of 18 studies and more than 363,000 people found no significant pooled association between long-term pollution and acceleration of the Horvath clock or GrimAge. This held even though most individual studies reported positive results. That pattern usually points to heterogeneity, small-study effects or publication bias rather than a hidden true effect.

Magnitude matters. In the UK Biobank, where the air is relatively clean, an interquartile rise in fine particles was tied to about three weeks of extra biological age. Among older Chinese adults, each additional 10 micrograms of PM2.5 per cubic meter raised frailty risk by about 5 percent. Some headline figures are much larger, such as three extra years of biological age per interquartile rise in ultrafine particles. That figure comes from a single cross-sectional study of COPD patients and should not be generalized.

The review’s boldest claim is that biological aging sits on the causal path from dirty air to disease. In the authors’ own analysis of two cohorts, aging measures statistically accounted for roughly a tenth to a half of the link between pollution and death. Mediation analysis of observational data is fragile, however. Income, smoking and chronic illness all track with both pollution exposure and faster aging.

There is some encouraging news. Chinese households that switched from coal or wood to clean cooking fuel showed slower biological aging and much lower frailty risk. Regions where air quality improved saw slower frailty progression. None of these comparisons were randomized.

The central idea is plausible and important: pollution looks less like a list of separate diseases and more like a general accelerant of aging. The evidence that it moves molecular clocks, the tests biohackers actually buy, is still unconvincing.

Actionable Insights

Indoor air is the part you control, and it shows the clearest harm. Cooking or heating with solid fuels (coal, wood, biomass) carried a pooled 28 percent higher risk of frailty. In one large Chinese cohort, switching to clean fuel cut frailty risk by a third to two thirds. This review does not assess gas stoves or home HEPA filtration. The authors list filtration trials as an unmet research need.

For a typical Western city dweller, the numbers are modest. Each 10 microgram drop in long-term PM2.5 was associated with about 5 percent lower relative frailty risk. If your baseline risk were 15 percent, that change would take it to about 14.3 percent. For one person this is small, but across a population it is large.

The risk curve steepened above about 50 micrograms per cubic meter. Protecting yourself on bad days, such as wildfire smoke or heavy traffic, targets the steepest part of that curve. An N95 mask, staying indoors and running a filter all apply here.

Regular physical activity weakened the frailty risk from solid-fuel exposure and increased the benefit of switching fuels.

Do not use consumer epigenetic clock tests to track pollution effects. At the population level, the noise exceeds the signal.

Wildfire smoke is biomass combustion, so it is chemically close to the household wood and coal smoke the authors discuss than to traffic exhaust. It is rich in organic carbon, black carbon and PAHs, all of which have high oxidative potential.

Context and Source

  • Open Access Paper: Aging in the air we breathe: Mechanisms and consequences of air pollution exposure for biological aging, Published 19 August 2026.
  • Institutions: Tampere University (Faculty of Medicine and Health Technology); Karolinska Institutet; University of Oulu
  • Countries: Finland and Sweden
  • Journal: Ageing Research Reviews
  • Impact evaluation: The impact score of this journal is 15.5, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a High impact journal.

Leitura Relacionada: